Home » Posts tagged with » cancer
What is Cancer? Types of Cancer & Symptoms of Cancer

What is Cancer? Types of Cancer & Symptoms of Cancer

Cancer has become a common term nowadays as most of the people are being diagnosed with different types of cancer. Cancer means abnormal and unregulated proliferation of cells from a specific organ with the ability to create their own blood supply and break away from the origin and spread to other parts of the body. […]

Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Continue reading …
PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors

PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]

Continue reading …
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798

Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Roche’s cancer drug Rituxan (rituximab). Rituxan, which is a CD20-directed cytolytic antibody, has approval across various regions for the […]

Continue reading …
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer

Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) for the treatment of advanced urothelial cancer, the most common form of bladder cancer. Padcev, which has been co-developed by the two pharma companies, is a Nectin-4-directed antibody and microtubule […]

Continue reading …
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) in patients who are treatment-naïve. The US pharma company is aiming to enroll 400 patients in the late-stage clinical trial. The patients will be grouped randomly to be subjected to […]

Continue reading …
Precision oncology company Black Diamond Therapeutics raises $85m

Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of the Tavistock Group. Additional new investors in the Series C round included Wellington Management Company, BVF Partners, Deerfield Management, funds managed by Janus Henderson Investors, Logos Capital, and Casdin Capital. […]

Continue reading …
Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL

US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]

Continue reading …
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies

Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]

Continue reading …
LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial

Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial of TBC-1002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and has now initiated a phase 2 A clinical trial. The US pharma company, which is a subsidiary of California-based TesoRx Pharma, said that the phase […]

Continue reading …
Page 1 of 7123Next ›Last »